nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIS—prostate gland—urinary bladder cancer	0.0232	0.121	CbGeAlD
Epoprostenol—P2RY12—prostate gland—urinary bladder cancer	0.0209	0.109	CbGeAlD
Epoprostenol—PTGIS—smooth muscle tissue—urinary bladder cancer	0.0164	0.0858	CbGeAlD
Epoprostenol—P2RY12—epithelium—urinary bladder cancer	0.0154	0.0802	CbGeAlD
Epoprostenol—PTGER1—renal system—urinary bladder cancer	0.0147	0.0768	CbGeAlD
Epoprostenol—PTGIR—prostate gland—urinary bladder cancer	0.0133	0.0696	CbGeAlD
Epoprostenol—CYP2C9—urine—urinary bladder cancer	0.0133	0.0693	CbGeAlD
Epoprostenol—PTGIS—female reproductive system—urinary bladder cancer	0.0127	0.0662	CbGeAlD
Epoprostenol—PTGER1—female reproductive system—urinary bladder cancer	0.0118	0.0615	CbGeAlD
Epoprostenol—PTGIR—epithelium—urinary bladder cancer	0.0098	0.0511	CbGeAlD
Epoprostenol—PTGIR—smooth muscle tissue—urinary bladder cancer	0.00944	0.0493	CbGeAlD
Epoprostenol—PTGIR—renal system—urinary bladder cancer	0.00909	0.0474	CbGeAlD
Epoprostenol—Dinoprost Tromethamine—HPGDS—urinary bladder cancer	0.00903	0.565	CrCbGaD
Epoprostenol—PTGIS—lymph node—urinary bladder cancer	0.00741	0.0387	CbGeAlD
Epoprostenol—PTGIR—female reproductive system—urinary bladder cancer	0.00728	0.038	CbGeAlD
Epoprostenol—Dinoprostone—HPGDS—urinary bladder cancer	0.00694	0.435	CrCbGaD
Epoprostenol—PTGIR—lymph node—urinary bladder cancer	0.00426	0.0222	CbGeAlD
Epoprostenol—CYP2C9—female reproductive system—urinary bladder cancer	0.0026	0.0136	CbGeAlD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000742	0.00282	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SLC19A1—urinary bladder cancer	0.00074	0.00281	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—UGT2B7—urinary bladder cancer	0.000728	0.00277	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PRSS3—urinary bladder cancer	0.000721	0.00274	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000688	0.00262	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HDAC4—urinary bladder cancer	0.000688	0.00262	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000679	0.00258	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CYP4B1—urinary bladder cancer	0.000656	0.0025	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.00062	0.00236	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—SLC19A1—urinary bladder cancer	0.000619	0.00236	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000611	0.00233	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PRSS3—urinary bladder cancer	0.000604	0.0023	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—TNF—urinary bladder cancer	0.0006	0.00228	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	0.000558	0.00212	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—LIG1—urinary bladder cancer	0.000546	0.00208	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000534	0.00203	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000524	0.00199	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	0.000511	0.00194	CbGpPWpGaD
Epoprostenol—Pneumonia—Epirubicin—urinary bladder cancer	0.000506	0.000956	CcSEcCtD
Epoprostenol—Infestation NOS—Epirubicin—urinary bladder cancer	0.000503	0.00095	CcSEcCtD
Epoprostenol—Infestation—Epirubicin—urinary bladder cancer	0.000503	0.00095	CcSEcCtD
Epoprostenol—Rash—Thiotepa—urinary bladder cancer	0.000503	0.000949	CcSEcCtD
Epoprostenol—Dermatitis—Thiotepa—urinary bladder cancer	0.000502	0.000948	CcSEcCtD
Epoprostenol—Headache—Thiotepa—urinary bladder cancer	0.000499	0.000943	CcSEcCtD
Epoprostenol—Decreased appetite—Etoposide—urinary bladder cancer	0.000498	0.00094	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—IFNA2—urinary bladder cancer	0.000497	0.00189	CbGpPWpGaD
Epoprostenol—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000496	0.000936	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000494	0.000933	CcSEcCtD
Epoprostenol—Body temperature increased—Cisplatin—urinary bladder cancer	0.000494	0.000933	CcSEcCtD
Epoprostenol—Fatigue—Etoposide—urinary bladder cancer	0.000494	0.000932	CcSEcCtD
Epoprostenol—Constipation—Etoposide—urinary bladder cancer	0.00049	0.000924	CcSEcCtD
Epoprostenol—Pain—Etoposide—urinary bladder cancer	0.00049	0.000924	CcSEcCtD
Epoprostenol—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000489	0.000924	CcSEcCtD
Epoprostenol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000486	0.000917	CcSEcCtD
Epoprostenol—Haemoglobin—Methotrexate—urinary bladder cancer	0.000485	0.000916	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000484	0.00184	CbGpPWpGaD
Epoprostenol—Haemorrhage—Methotrexate—urinary bladder cancer	0.000483	0.000911	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—TYMP—urinary bladder cancer	0.000483	0.00184	CbGpPWpGaD
Epoprostenol—Sweating—Epirubicin—urinary bladder cancer	0.000482	0.000911	CcSEcCtD
Epoprostenol—Asthenia—Gemcitabine—urinary bladder cancer	0.000481	0.000908	CcSEcCtD
Epoprostenol—Haematuria—Epirubicin—urinary bladder cancer	0.00048	0.000906	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—urinary bladder cancer	0.000479	0.000905	CcSEcCtD
Epoprostenol—Epistaxis—Epirubicin—urinary bladder cancer	0.000475	0.000896	CcSEcCtD
Epoprostenol—Pruritus—Gemcitabine—urinary bladder cancer	0.000474	0.000896	CcSEcCtD
Epoprostenol—Nausea—Thiotepa—urinary bladder cancer	0.000473	0.000894	CcSEcCtD
Epoprostenol—Weight decreased—Doxorubicin—urinary bladder cancer	0.000472	0.000892	CcSEcCtD
Epoprostenol—Sinusitis—Epirubicin—urinary bladder cancer	0.000472	0.000891	CcSEcCtD
Epoprostenol—Pneumonia—Doxorubicin—urinary bladder cancer	0.000468	0.000884	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000468	0.000884	CcSEcCtD
Epoprostenol—Pruritus—Fluorouracil—urinary bladder cancer	0.000466	0.000881	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000466	0.000879	CcSEcCtD
Epoprostenol—Infestation—Doxorubicin—urinary bladder cancer	0.000466	0.000879	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000463	0.00176	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00046	0.000869	CcSEcCtD
Epoprostenol—Bradycardia—Epirubicin—urinary bladder cancer	0.00046	0.000868	CcSEcCtD
Epoprostenol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000459	0.000866	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—IFNA2—urinary bladder cancer	0.000458	0.00174	CbGpPWpGaD
Epoprostenol—Urticaria—Etoposide—urinary bladder cancer	0.000455	0.000859	CcSEcCtD
Epoprostenol—Haemoglobin—Epirubicin—urinary bladder cancer	0.000454	0.000857	CcSEcCtD
Epoprostenol—Rhinitis—Epirubicin—urinary bladder cancer	0.000453	0.000855	CcSEcCtD
Epoprostenol—Body temperature increased—Etoposide—urinary bladder cancer	0.000453	0.000855	CcSEcCtD
Epoprostenol—Abdominal pain—Etoposide—urinary bladder cancer	0.000453	0.000855	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000453	0.000855	CcSEcCtD
Epoprostenol—Haemorrhage—Epirubicin—urinary bladder cancer	0.000452	0.000853	CcSEcCtD
Epoprostenol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000451	0.000852	CcSEcCtD
Epoprostenol—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000449	0.000849	CcSEcCtD
Epoprostenol—Asthenia—Cisplatin—urinary bladder cancer	0.000448	0.000847	CcSEcCtD
Epoprostenol—Pharyngitis—Epirubicin—urinary bladder cancer	0.000448	0.000847	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000448	0.000846	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—urinary bladder cancer	0.000446	0.000843	CcSEcCtD
Epoprostenol—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000445	0.00084	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—urinary bladder cancer	0.000444	0.000838	CcSEcCtD
Epoprostenol—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000444	0.000838	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—urinary bladder cancer	0.000439	0.000829	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—urinary bladder cancer	0.000438	0.000827	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—urinary bladder cancer	0.000437	0.000825	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—NAT2—urinary bladder cancer	0.000436	0.00166	CbGpPWpGaD
Epoprostenol—Dizziness—Fluorouracil—urinary bladder cancer	0.000436	0.000823	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000435	0.000821	CcSEcCtD
Epoprostenol—Chills—Methotrexate—urinary bladder cancer	0.000433	0.000818	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	0.000429	0.00163	CbGpPWpGaD
Epoprostenol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000428	0.000807	CcSEcCtD
Epoprostenol—P2RY12—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000427	0.00162	CbGpPWpGaD
Epoprostenol—Vomiting—Gemcitabine—urinary bladder cancer	0.000426	0.000805	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—urinary bladder cancer	0.000425	0.000803	CcSEcCtD
Epoprostenol—Mental disorder—Methotrexate—urinary bladder cancer	0.000423	0.000798	CcSEcCtD
Epoprostenol—Rash—Gemcitabine—urinary bladder cancer	0.000423	0.000798	CcSEcCtD
Epoprostenol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000422	0.000797	CcSEcCtD
Epoprostenol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000422	0.000796	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00042	0.000793	CcSEcCtD
Epoprostenol—Headache—Gemcitabine—urinary bladder cancer	0.00042	0.000793	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000419	0.000792	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—urinary bladder cancer	0.000419	0.000792	CcSEcCtD
Epoprostenol—Vomiting—Fluorouracil—urinary bladder cancer	0.000419	0.000791	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—urinary bladder cancer	0.000419	0.000791	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000418	0.000789	CcSEcCtD
Epoprostenol—PTGIS—Disease—ENO2—urinary bladder cancer	0.000417	0.00158	CbGpPWpGaD
Epoprostenol—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000416	0.000785	CcSEcCtD
Epoprostenol—Rash—Fluorouracil—urinary bladder cancer	0.000416	0.000785	CcSEcCtD
Epoprostenol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000415	0.000784	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000415	0.000783	CcSEcCtD
Epoprostenol—Headache—Fluorouracil—urinary bladder cancer	0.000413	0.00078	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000412	0.00157	CbGpPWpGaD
Epoprostenol—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000412	0.000777	CcSEcCtD
Epoprostenol—Asthenia—Etoposide—urinary bladder cancer	0.000411	0.000776	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000411	0.000776	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—urinary bladder cancer	0.00041	0.000774	CcSEcCtD
Epoprostenol—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000407	0.000769	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000407	0.00155	CbGpPWpGaD
Epoprostenol—Back pain—Methotrexate—urinary bladder cancer	0.000406	0.000767	CcSEcCtD
Epoprostenol—Chills—Epirubicin—urinary bladder cancer	0.000405	0.000765	CcSEcCtD
Epoprostenol—Pruritus—Etoposide—urinary bladder cancer	0.000405	0.000765	CcSEcCtD
Epoprostenol—Nausea—Gemcitabine—urinary bladder cancer	0.000398	0.000752	CcSEcCtD
Epoprostenol—Vomiting—Cisplatin—urinary bladder cancer	0.000397	0.00075	CcSEcCtD
Epoprostenol—Mental disorder—Epirubicin—urinary bladder cancer	0.000396	0.000747	CcSEcCtD
Epoprostenol—PTGIS—Disease—RBX1—urinary bladder cancer	0.000395	0.0015	CbGpPWpGaD
Epoprostenol—Rash—Cisplatin—urinary bladder cancer	0.000394	0.000744	CcSEcCtD
Epoprostenol—Dermatitis—Cisplatin—urinary bladder cancer	0.000394	0.000743	CcSEcCtD
Epoprostenol—Diarrhoea—Etoposide—urinary bladder cancer	0.000392	0.00074	CcSEcCtD
Epoprostenol—Nausea—Fluorouracil—urinary bladder cancer	0.000392	0.000739	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—urinary bladder cancer	0.000388	0.000733	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000388	0.000732	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—urinary bladder cancer	0.000388	0.000732	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—urinary bladder cancer	0.000387	0.000732	CcSEcCtD
Epoprostenol—Tension—Epirubicin—urinary bladder cancer	0.000386	0.000729	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—HDAC4—urinary bladder cancer	0.000383	0.00146	CbGpPWpGaD
Epoprostenol—Nervousness—Epirubicin—urinary bladder cancer	0.000382	0.000721	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—urinary bladder cancer	0.00038	0.000718	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—urinary bladder cancer	0.000379	0.000716	CcSEcCtD
Epoprostenol—Dizziness—Etoposide—urinary bladder cancer	0.000379	0.000715	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—urinary bladder cancer	0.000378	0.000714	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—RRM2—urinary bladder cancer	0.000377	0.00143	CbGpPWpGaD
Epoprostenol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000377	0.000711	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—urinary bladder cancer	0.000375	0.000708	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	0.000374	0.00142	CbGpPWpGaD
Epoprostenol—Nausea—Cisplatin—urinary bladder cancer	0.000371	0.000701	CcSEcCtD
Epoprostenol—Cough—Methotrexate—urinary bladder cancer	0.000367	0.000692	CcSEcCtD
Epoprostenol—Mental disorder—Doxorubicin—urinary bladder cancer	0.000366	0.000691	CcSEcCtD
Epoprostenol—Vomiting—Etoposide—urinary bladder cancer	0.000364	0.000687	CcSEcCtD
Epoprostenol—Anaemia—Epirubicin—urinary bladder cancer	0.000363	0.000686	CcSEcCtD
Epoprostenol—Agitation—Epirubicin—urinary bladder cancer	0.000361	0.000682	CcSEcCtD
Epoprostenol—Rash—Etoposide—urinary bladder cancer	0.000361	0.000682	CcSEcCtD
Epoprostenol—Dermatitis—Etoposide—urinary bladder cancer	0.000361	0.000681	CcSEcCtD
Epoprostenol—Headache—Etoposide—urinary bladder cancer	0.000359	0.000677	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—urinary bladder cancer	0.000359	0.000677	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—urinary bladder cancer	0.000358	0.000675	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—urinary bladder cancer	0.000358	0.000675	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—urinary bladder cancer	0.000358	0.000675	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—urinary bladder cancer	0.000357	0.000674	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000355	0.000671	CcSEcCtD
Epoprostenol—PTGIS—Disease—JAG1—urinary bladder cancer	0.000353	0.00134	CbGpPWpGaD
Epoprostenol—Nervousness—Doxorubicin—urinary bladder cancer	0.000353	0.000667	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—PLAU—urinary bladder cancer	0.000353	0.00134	CbGpPWpGaD
Epoprostenol—Syncope—Epirubicin—urinary bladder cancer	0.000353	0.000666	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—HDAC4—urinary bladder cancer	0.000352	0.00134	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000352	0.00134	CbGpPWpGaD
Epoprostenol—Back pain—Doxorubicin—urinary bladder cancer	0.000352	0.000665	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00035	0.000661	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—ENO2—urinary bladder cancer	0.000349	0.00133	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—HPGDS—urinary bladder cancer	0.000349	0.00133	CbGpPWpGaD
Epoprostenol—Palpitations—Epirubicin—urinary bladder cancer	0.000347	0.000656	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000347	0.00132	CbGpPWpGaD
Epoprostenol—Confusional state—Methotrexate—urinary bladder cancer	0.000346	0.000653	CcSEcCtD
Epoprostenol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000346	0.000653	CcSEcCtD
Epoprostenol—Cough—Epirubicin—urinary bladder cancer	0.000343	0.000648	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000343	0.000648	CcSEcCtD
Epoprostenol—Infection—Methotrexate—urinary bladder cancer	0.000341	0.000643	CcSEcCtD
Epoprostenol—Nausea—Etoposide—urinary bladder cancer	0.00034	0.000642	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000339	0.00129	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTT1—urinary bladder cancer	0.000338	0.00129	CbGpPWpGaD
Epoprostenol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000336	0.000635	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—urinary bladder cancer	0.000336	0.000635	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000336	0.000634	CcSEcCtD
Epoprostenol—Chest pain—Epirubicin—urinary bladder cancer	0.000335	0.000632	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—urinary bladder cancer	0.000335	0.000632	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—urinary bladder cancer	0.000335	0.000632	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—urinary bladder cancer	0.000334	0.000631	CcSEcCtD
Epoprostenol—Anxiety—Epirubicin—urinary bladder cancer	0.000334	0.00063	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000333	0.00127	CbGpPWpGaD
Epoprostenol—Skin disorder—Methotrexate—urinary bladder cancer	0.000333	0.000629	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000332	0.000628	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000332	0.000626	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.00033	0.00125	CbGpPWpGaD
Epoprostenol—Dry mouth—Epirubicin—urinary bladder cancer	0.000327	0.000618	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—urinary bladder cancer	0.000327	0.000617	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—urinary bladder cancer	0.000326	0.000616	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—PLAU—urinary bladder cancer	0.000325	0.00124	CbGpPWpGaD
Epoprostenol—Confusional state—Epirubicin—urinary bladder cancer	0.000324	0.000611	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—urinary bladder cancer	0.000322	0.000607	CcSEcCtD
Epoprostenol—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000321	0.000606	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—urinary bladder cancer	0.000321	0.000606	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—GLI1—urinary bladder cancer	0.000321	0.00122	CbGpPWpGaD
Epoprostenol—Hypotension—Methotrexate—urinary bladder cancer	0.00032	0.000605	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00032	0.000604	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.00032	0.00122	CbGpPWpGaD
Epoprostenol—Infection—Epirubicin—urinary bladder cancer	0.000319	0.000602	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—urinary bladder cancer	0.000317	0.000599	CcSEcCtD
Epoprostenol—Shock—Epirubicin—urinary bladder cancer	0.000316	0.000596	CcSEcCtD
Epoprostenol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000315	0.000594	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000314	0.000593	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—urinary bladder cancer	0.000313	0.000591	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000312	0.00059	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000312	0.00119	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000312	0.00119	CbGpPWpGaD
Epoprostenol—Skin disorder—Epirubicin—urinary bladder cancer	0.000312	0.000589	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00031	0.000586	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—urinary bladder cancer	0.00031	0.000586	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—urinary bladder cancer	0.00031	0.000585	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—urinary bladder cancer	0.00031	0.000585	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—urinary bladder cancer	0.00031	0.000585	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—urinary bladder cancer	0.000309	0.000583	CcSEcCtD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000308	0.00117	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.000308	0.00117	CbGpPWpGaD
Epoprostenol—Paraesthesia—Methotrexate—urinary bladder cancer	0.000308	0.000581	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000308	0.000581	CcSEcCtD
Epoprostenol—Anorexia—Epirubicin—urinary bladder cancer	0.000306	0.000578	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000306	0.000577	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—urinary bladder cancer	0.000305	0.000576	CcSEcCtD
Epoprostenol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000303	0.000572	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000302	0.00057	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—urinary bladder cancer	0.0003	0.000566	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—urinary bladder cancer	0.000299	0.000565	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—urinary bladder cancer	0.000298	0.000563	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—urinary bladder cancer	0.000297	0.000561	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000297	0.000561	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000296	0.000559	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—urinary bladder cancer	0.000296	0.000558	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—GLI1—urinary bladder cancer	0.000295	0.00112	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GLI1—urinary bladder cancer	0.000295	0.00112	CbGpPWpGaD
Epoprostenol—Infection—Doxorubicin—urinary bladder cancer	0.000295	0.000557	CcSEcCtD
Epoprostenol—Pain—Methotrexate—urinary bladder cancer	0.000293	0.000554	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000292	0.000552	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—urinary bladder cancer	0.000292	0.000552	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	0.000291	0.00111	CbGpPWpGaD
Epoprostenol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000291	0.00055	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—CREBBP—urinary bladder cancer	0.000291	0.00111	CbGpPWpGaD
Epoprostenol—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000291	0.000549	CcSEcCtD
Epoprostenol—Insomnia—Epirubicin—urinary bladder cancer	0.00029	0.000548	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—urinary bladder cancer	0.00029	0.000547	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—urinary bladder cancer	0.000288	0.000545	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—urinary bladder cancer	0.000288	0.000544	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—IGF1—urinary bladder cancer	0.000287	0.00109	CbGpPWpGaD
Epoprostenol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000287	0.000542	CcSEcCtD
Epoprostenol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000286	0.00054	CcSEcCtD
Epoprostenol—Somnolence—Epirubicin—urinary bladder cancer	0.000285	0.000539	CcSEcCtD
Epoprostenol—Anorexia—Doxorubicin—urinary bladder cancer	0.000283	0.000534	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000282	0.000533	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—NQO1—urinary bladder cancer	0.000281	0.00107	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00028	0.000529	CcSEcCtD
Epoprostenol—Decreased appetite—Epirubicin—urinary bladder cancer	0.000279	0.000527	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—urinary bladder cancer	0.000277	0.000524	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000277	0.000523	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—urinary bladder cancer	0.000277	0.000522	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—urinary bladder cancer	0.000274	0.000518	CcSEcCtD
Epoprostenol—Pain—Epirubicin—urinary bladder cancer	0.000274	0.000518	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000273	0.00104	CbGpPWpGaD
Epoprostenol—Urticaria—Methotrexate—urinary bladder cancer	0.000272	0.000514	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—urinary bladder cancer	0.000271	0.000512	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000271	0.000512	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000271	0.000511	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—urinary bladder cancer	0.000269	0.000507	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—CREBBP—urinary bladder cancer	0.000268	0.00102	CbGpPWpGaD
Epoprostenol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000267	0.000503	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000265	0.0005	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—IGF1—urinary bladder cancer	0.000265	0.00101	CbGpPWpGaD
Epoprostenol—Somnolence—Doxorubicin—urinary bladder cancer	0.000264	0.000498	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—RHOA—urinary bladder cancer	0.000263	0.001	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000262	0.000496	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000261	0.000494	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000259	0.000983	CbGpPWpGaD
Epoprostenol—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000258	0.000487	CcSEcCtD
Epoprostenol—PTGIS—Disease—NCOR1—urinary bladder cancer	0.000257	0.000979	CbGpPWpGaD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000256	0.000484	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—urinary bladder cancer	0.000256	0.000483	CcSEcCtD
Epoprostenol—Urticaria—Epirubicin—urinary bladder cancer	0.000255	0.000481	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—urinary bladder cancer	0.000254	0.000479	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—urinary bladder cancer	0.000254	0.000479	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—urinary bladder cancer	0.000254	0.000479	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—urinary bladder cancer	0.000254	0.000479	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000253	0.000477	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	0.000248	0.000942	CbGpPWpGaD
Epoprostenol—Asthenia—Methotrexate—urinary bladder cancer	0.000246	0.000465	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000243	0.000458	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—urinary bladder cancer	0.000243	0.000458	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—RHOA—urinary bladder cancer	0.000242	0.000922	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ERCC2—urinary bladder cancer	0.000242	0.00092	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000238	0.000905	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000238	0.000905	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000238	0.000905	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000238	0.000905	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000236	0.000446	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—urinary bladder cancer	0.000236	0.000445	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000235	0.000443	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000235	0.000443	CcSEcCtD
Epoprostenol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000235	0.000443	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—GSTP1—urinary bladder cancer	0.000235	0.000892	CbGpPWpGaD
Epoprostenol—Asthenia—Epirubicin—urinary bladder cancer	0.00023	0.000435	CcSEcCtD
Epoprostenol—PTGIS—Disease—MTHFR—urinary bladder cancer	0.000227	0.000865	CbGpPWpGaD
Epoprostenol—Pruritus—Epirubicin—urinary bladder cancer	0.000227	0.000429	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000227	0.000863	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TERT—urinary bladder cancer	0.000227	0.000863	CbGpPWpGaD
Epoprostenol—Dizziness—Methotrexate—urinary bladder cancer	0.000227	0.000428	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000222	0.000843	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—IL2—urinary bladder cancer	0.000221	0.00084	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RBX1—urinary bladder cancer	0.00022	0.000837	CbGpPWpGaD
Epoprostenol—Diarrhoea—Epirubicin—urinary bladder cancer	0.00022	0.000415	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000219	0.000413	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000219	0.000831	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—TYMS—urinary bladder cancer	0.000218	0.000829	CbGpPWpGaD
Epoprostenol—Vomiting—Methotrexate—urinary bladder cancer	0.000218	0.000412	CcSEcCtD
Epoprostenol—Rash—Methotrexate—urinary bladder cancer	0.000216	0.000408	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—urinary bladder cancer	0.000216	0.000408	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—NCOR1—urinary bladder cancer	0.000216	0.00082	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTM1—urinary bladder cancer	0.000216	0.00082	CbGpPWpGaD
Epoprostenol—Headache—Methotrexate—urinary bladder cancer	0.000215	0.000406	CcSEcCtD
Epoprostenol—Asthenia—Doxorubicin—urinary bladder cancer	0.000213	0.000402	CcSEcCtD
Epoprostenol—Dizziness—Epirubicin—urinary bladder cancer	0.000212	0.000401	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—urinary bladder cancer	0.00021	0.000397	CcSEcCtD
Epoprostenol—PTGIS—Disease—FGFR3—urinary bladder cancer	0.000208	0.000792	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TSC1—urinary bladder cancer	0.000207	0.000787	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GPX1—urinary bladder cancer	0.000206	0.000785	CbGpPWpGaD
Epoprostenol—Vomiting—Epirubicin—urinary bladder cancer	0.000204	0.000385	CcSEcCtD
Epoprostenol—Nausea—Methotrexate—urinary bladder cancer	0.000204	0.000385	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000204	0.000775	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IL2—urinary bladder cancer	0.000203	0.000773	CbGpPWpGaD
Epoprostenol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000203	0.000384	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—ERCC2—urinary bladder cancer	0.000203	0.000771	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RBX1—urinary bladder cancer	0.000202	0.00077	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RBX1—urinary bladder cancer	0.000202	0.00077	CbGpPWpGaD
Epoprostenol—Rash—Epirubicin—urinary bladder cancer	0.000202	0.000382	CcSEcCtD
Epoprostenol—Dermatitis—Epirubicin—urinary bladder cancer	0.000202	0.000382	CcSEcCtD
Epoprostenol—Headache—Epirubicin—urinary bladder cancer	0.000201	0.00038	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000201	0.000764	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—EP300—urinary bladder cancer	0.000198	0.000754	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JAG1—urinary bladder cancer	0.000197	0.000749	CbGpPWpGaD
Epoprostenol—Dizziness—Doxorubicin—urinary bladder cancer	0.000196	0.000371	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—SRC—urinary bladder cancer	0.000193	0.000733	CbGpPWpGaD
Epoprostenol—Nausea—Epirubicin—urinary bladder cancer	0.000191	0.00036	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—MTHFR—urinary bladder cancer	0.00019	0.000725	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TSC1—urinary bladder cancer	0.00019	0.000724	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TSC1—urinary bladder cancer	0.00019	0.000724	CbGpPWpGaD
Epoprostenol—Vomiting—Doxorubicin—urinary bladder cancer	0.000189	0.000356	CcSEcCtD
Epoprostenol—Rash—Doxorubicin—urinary bladder cancer	0.000187	0.000354	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—urinary bladder cancer	0.000187	0.000353	CcSEcCtD
Epoprostenol—Headache—Doxorubicin—urinary bladder cancer	0.000186	0.000351	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—EP300—urinary bladder cancer	0.000182	0.000694	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JAG1—urinary bladder cancer	0.000181	0.000689	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JAG1—urinary bladder cancer	0.000181	0.000689	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—SRC—urinary bladder cancer	0.000177	0.000675	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CREBBP—urinary bladder cancer	0.000177	0.000674	CbGpPWpGaD
Epoprostenol—Nausea—Doxorubicin—urinary bladder cancer	0.000176	0.000333	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000166	0.000633	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—RHOA—urinary bladder cancer	0.00016	0.00061	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—KRAS—urinary bladder cancer	0.00016	0.000607	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—S100B—urinary bladder cancer	0.000159	0.000606	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PPARG—urinary bladder cancer	0.000154	0.000588	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000153	0.000583	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000153	0.000583	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—RHOA—urinary bladder cancer	0.000151	0.000575	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CREBBP—urinary bladder cancer	0.000148	0.000564	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ERBB2—urinary bladder cancer	0.000148	0.000564	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—KRAS—urinary bladder cancer	0.000147	0.000559	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—S100B—urinary bladder cancer	0.000147	0.000558	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—S100B—urinary bladder cancer	0.000147	0.000558	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000146	0.000556	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—urinary bladder cancer	0.000145	0.000552	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NCOR1—urinary bladder cancer	0.000143	0.000545	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—urinary bladder cancer	0.000142	0.00054	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL2—urinary bladder cancer	0.00014	0.000531	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—RHOA—urinary bladder cancer	0.000139	0.000529	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—RHOA—urinary bladder cancer	0.000139	0.000529	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000136	0.000516	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—HRAS—urinary bladder cancer	0.000136	0.000516	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000134	0.000511	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000134	0.000511	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000133	0.000505	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NCOR1—urinary bladder cancer	0.000132	0.000502	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NCOR1—urinary bladder cancer	0.000132	0.000502	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—urinary bladder cancer	0.000131	0.000497	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000129	0.00049	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000129	0.00049	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL2—urinary bladder cancer	0.000128	0.000489	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL2—urinary bladder cancer	0.000128	0.000489	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN1A—urinary bladder cancer	0.000127	0.000482	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2—urinary bladder cancer	0.000127	0.000482	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000127	0.000482	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTEN—urinary bladder cancer	0.000127	0.000481	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TERT—urinary bladder cancer	0.000126	0.000481	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—urinary bladder cancer	0.000125	0.000475	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000122	0.000464	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000122	0.000464	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—urinary bladder cancer	0.000122	0.000462	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EP300—urinary bladder cancer	0.000121	0.000459	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	0.000118	0.000448	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SRC—urinary bladder cancer	0.000117	0.000446	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2—urinary bladder cancer	0.000117	0.000444	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2—urinary bladder cancer	0.000117	0.000444	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TERT—urinary bladder cancer	0.000116	0.000442	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TERT—urinary bladder cancer	0.000116	0.000442	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGFR3—urinary bladder cancer	0.000116	0.000441	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ESR1—urinary bladder cancer	0.000113	0.000428	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGFR3—urinary bladder cancer	0.000107	0.000406	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGFR3—urinary bladder cancer	0.000107	0.000406	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	0.000106	0.000403	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTEN—urinary bladder cancer	0.000106	0.000403	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—urinary bladder cancer	0.000105	0.0004	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ESR1—urinary bladder cancer	0.000104	0.000394	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ESR1—urinary bladder cancer	0.000104	0.000394	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—urinary bladder cancer	0.000103	0.000391	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—EP300—urinary bladder cancer	0.000101	0.000384	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	0.0001	0.000381	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CREBBP—urinary bladder cancer	9.87e-05	0.000375	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	9.75e-05	0.000371	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1—urinary bladder cancer	9.74e-05	0.000371	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—urinary bladder cancer	9.72e-05	0.00037	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—urinary bladder cancer	9.7e-05	0.000369	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—urinary bladder cancer	9.16e-05	0.000348	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CREBBP—urinary bladder cancer	9.08e-05	0.000345	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CREBBP—urinary bladder cancer	9.08e-05	0.000345	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1—urinary bladder cancer	8.97e-05	0.000341	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1—urinary bladder cancer	8.97e-05	0.000341	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RHOA—urinary bladder cancer	8.93e-05	0.00034	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—urinary bladder cancer	8.92e-05	0.000339	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—urinary bladder cancer	8.92e-05	0.000339	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—urinary bladder cancer	8.43e-05	0.000321	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—urinary bladder cancer	8.43e-05	0.000321	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB2—urinary bladder cancer	8.26e-05	0.000314	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—urinary bladder cancer	8.26e-05	0.000314	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RHOA—urinary bladder cancer	8.22e-05	0.000313	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RHOA—urinary bladder cancer	8.22e-05	0.000313	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—urinary bladder cancer	7.84e-05	0.000298	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.82e-05	0.000297	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMP—urinary bladder cancer	7.8e-05	0.000297	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—urinary bladder cancer	7.79e-05	0.000296	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB2—urinary bladder cancer	7.61e-05	0.000289	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB2—urinary bladder cancer	7.61e-05	0.000289	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—urinary bladder cancer	7.49e-05	0.000285	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.49e-05	0.000285	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—urinary bladder cancer	7.3e-05	0.000278	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—urinary bladder cancer	7.21e-05	0.000274	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—urinary bladder cancer	7.21e-05	0.000274	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—urinary bladder cancer	7.17e-05	0.000273	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—urinary bladder cancer	7.17e-05	0.000273	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—urinary bladder cancer	7.09e-05	0.00027	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1A—urinary bladder cancer	7.06e-05	0.000269	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NAT2—urinary bladder cancer	7.05e-05	0.000268	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—urinary bladder cancer	7.05e-05	0.000268	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—urinary bladder cancer	6.89e-05	0.000262	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—urinary bladder cancer	6.89e-05	0.000262	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EP300—urinary bladder cancer	6.72e-05	0.000256	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—urinary bladder cancer	6.72e-05	0.000256	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—urinary bladder cancer	6.72e-05	0.000256	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SRC—urinary bladder cancer	6.54e-05	0.000249	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—urinary bladder cancer	6.52e-05	0.000248	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—urinary bladder cancer	6.52e-05	0.000248	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.5e-05	0.000247	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1A—urinary bladder cancer	6.5e-05	0.000247	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—urinary bladder cancer	6.49e-05	0.000247	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—urinary bladder cancer	6.49e-05	0.000247	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EP300—urinary bladder cancer	6.18e-05	0.000235	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EP300—urinary bladder cancer	6.18e-05	0.000235	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—RRM2—urinary bladder cancer	6.09e-05	0.000232	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SRC—urinary bladder cancer	6.01e-05	0.000229	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SRC—urinary bladder cancer	6.01e-05	0.000229	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—urinary bladder cancer	5.86e-05	0.000223	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—urinary bladder cancer	5.73e-05	0.000218	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	5.64e-05	0.000214	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ENO2—urinary bladder cancer	5.64e-05	0.000214	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.6e-05	0.000213	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	5.47e-05	0.000208	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—urinary bladder cancer	5.41e-05	0.000206	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—urinary bladder cancer	5.39e-05	0.000205	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—urinary bladder cancer	5.39e-05	0.000205	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.38e-05	0.000205	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—urinary bladder cancer	5.27e-05	0.000201	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—urinary bladder cancer	5.27e-05	0.000201	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—urinary bladder cancer	4.98e-05	0.000189	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—urinary bladder cancer	4.98e-05	0.000189	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—urinary bladder cancer	4.81e-05	0.000183	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—urinary bladder cancer	4.6e-05	0.000175	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NQO1—urinary bladder cancer	4.54e-05	0.000173	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—urinary bladder cancer	4.43e-05	0.000168	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—urinary bladder cancer	4.43e-05	0.000168	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.41e-05	0.000168	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—urinary bladder cancer	4.23e-05	0.000161	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—urinary bladder cancer	4.23e-05	0.000161	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.84e-05	0.000146	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.79e-05	0.000144	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.67e-05	0.000139	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.52e-05	0.000134	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.48e-05	0.000132	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.48e-05	0.000132	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.34e-05	0.000127	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.27e-05	0.000125	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.08e-05	0.000117	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.5e-05	9.49e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.4e-05	9.12e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.96e-05	7.47e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.71e-05	6.51e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.63e-05	6.21e-05	CbGpPWpGaD
